TLE3 and breast carcinoma: In studies of ovarian and breast cancers, increased TLE3 expression was related to a higher response rate to taxane-based chemotherapy, but TLE3 expression showed no predictive value in treating breast cancer at an early stage (Samimi et al., 2012; Ring et al., 2018).